<DOC>
	<DOCNO>NCT01670890</DOCNO>
	<brief_summary>Temozolomide standard adjuvant chemotherapy newly-diagnosis malignant gliomas.Cisplatin , kind chemotherapeutics , enforce anti-tumor effect TMZ . Up , prognosis recurrent glioma pessimistic standard treatment procedure establish yet . The prospective , multicentre phase II clinical study evaluate efficacy safety TMZ CDDP patient recurrent malignant glioma</brief_summary>
	<brief_title>Efficacy Safety TMZ Plus CDDP Patients With Recurrent Malignant Gliomas</brief_title>
	<detailed_description />
	<mesh_term>Glioma</mesh_term>
	<mesh_term>Temozolomide</mesh_term>
	<mesh_term>Cisplatin</mesh_term>
	<mesh_term>Dacarbazine</mesh_term>
	<criteria>Written inform consent Age &gt; =18 &lt; =70years old Histological diagnosis malignant glioma ( WHO III IV ) The status methylation promotor MGMT detect . The time enrol 90 day irradiation . The patient recurrent gliomas treat nondosedense TMZ therapy enrollment . Performance status ( Karnofsky index ) &gt; =60 Life expectancy 3 month Ages : &lt; 18 year &gt; 70 year Abnormal function liver renal ( value 1.5 fold normal upper limit ) Blood routing : Hb &lt; 100g/l， WBC ＜ 4.0×109/l ; PLT &lt; 100×109/l Pregnant lactate woman Allergic administer drug Radiation treatment previous 90 day stereotactic radiation surgery within 60 day enrollment The patient recurrent gliomas treat dosedense TMZ therapy enrollment . Life expectancy le 3 month Participation clinical trial 90previous day enrollment</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>70 Years</maximum_age>
	<verification_date>August 2012</verification_date>
	<keyword>temozolomide ( TMZ )</keyword>
	<keyword>cisplatin ( CDDP )</keyword>
	<keyword>recurrent malignant glioma</keyword>
</DOC>